NEW YORK (GenomeWeb News) – Maternal and fetal health firm Carmenta Bioscience today said that it has raised more than $2 million in seed funding.

The Palo Alto, Calif.-based firm plans to use proceeds from the financing to continue development of its test for diagnosing preeclampsia in pregnant women and to commercialize the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.